secwatch.observer — SEC 8-K summary
======================================

Issuer:     OCULAR THERAPEUTIX, INC (OCUL)
CIK:        0001393434
Form:       8-K
Filed at:   2025-02-14T23:59:59+00:00
Accession:  0001104659-25-013473
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

CEO Dugel receives new compensation package with $819,200 salary, performance stock awards
--------------------------------------------------------------------------------

- Base salary raised to $819,200 annually; bonus target at 75% of salary; $368,100 2024 bonus plus $500,000 special one-time bonus.
- Time-Based RSU Award: 1,250,000 shares vesting over three years.
- Performance Awards: PSU up to 1,500,000 shares and Performance Option for 2,750,000 shares at $7.44 strike, tied to stock price hurdles from $15 to $30.
- Performance awards contingent on stockholder approval for 2021 Plan increase; no annual equity grant for 2026.
- Equity awards designed to align with long-term stockholder value; service-vesting through third anniversary.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1393434/000110465925013473/0001104659-25-013473-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1393434/000110465925013473/tm256644d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-013473

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer